Unlocking the Potential of IGFBP4 as a Drug Target and Biomarker

Target Name: IGFBP4

NCBI ID: G3487

IGFBP4

Unlocking the Potential of IGFBP4 as a Drug Target and Biomarker

Introduction

The insulin-like growth factor (IGF) signaling pathway is a crucial regulator of cellular growth and development, essential for the survival and proliferation of virtually all tissues. The IGF pathway has become a focus of intense research in recent years due to its potential as a therapeutic approach for various diseases, including obesity, diabetes, and cancer. One of the key proteins involved in this pathway is IGFBP4, which has been identified as a potential drug target and biomarker. In this article, we will explore the biology of IGFBP4 , its potential as a drug target, and its potential as a biomarker for various diseases.

Biography of IGFBP4

IGFBP4 is a 21-kDa protein that belongs to the IGFBP family. This family is characterized by the presence of a long N-terminus containing a putative nuclear localization signal (NLS), a transmembrane region, and a C-terminus containing a leucine- rich repeat (LRR) domain. IGFBP4 is expressed in various tissues, including adipose tissue, muscle, and bone, and has been shown to play a critical role in the regulation of cellular processes, including cell growth, differentiation, and survival.

IGFBP4 functions as a negative regulator of the IGF pathway. It inhibits the activity of the IGF receptor, which is a key transmembrane receptor that plays a central role in the regulation of cellular growth and development. The IGFBP4-IGF receptor interaction is highly specific, as IGFBP4 can inhibit the activity of both wild-type and mutant IGF receptors. This interaction between IGFBP4 and IGF receptors has significant implications for the development of IGFBP4-targeted therapies.

Potential Applications of IGFBP4 as a Drug Target

The IGF pathway has been identified as a potential therapeutic approach for various diseases, including obesity, diabetes, and cancer. One of the key reasons for this is the involvement of the IGFBP4 protein in this pathway. IGFBP4 has been shown to play a critical role in the regulation of cellular processes that are involved in the development and progression of these diseases.

For example, IGFBP4 has been shown to contribute to the regulation of obesity. Obesity is a complex disease that is characterized by the accumulation of excess body weight and a range of health problems. IGFBP4 has been shown to play a critical role in the regulation of obesity by affecting the activity of the IGF pathway. Several studies have shown that IGFBP4 can inhibit the activity of the IGF receptor in obese individuals, which can lead to decreased insulin sensitivity and an increased risk of obesity-related diseases.

IGFBP4 has also been shown to be involved in the regulation of cancer cell growth and survival. Cancer is a deadly disease that can be characterized by the rapid growth and spread of tumors. IGFBP4 has also been shown to play a critical role in the regulation of cancer cell growth and survival by affecting the activity of the IGF pathway. Several studies have shown that IGFBP4 can inhibit the activity of the IGF pathway in cancer cells, which can lead to the inhibition of their growth and the inhibition of their ability to migrate and invade.

In addition to its potential as a therapeutic target for cancer, IGFBP4 has also been shown to be involved in the regulation of other cellular processes that are critical for the development and progression of diseases. For example, IGFBP4 has been shown to play a critical role in the regulation of cell death, as it can

Protein Name: Insulin Like Growth Factor Binding Protein 4

Functions: IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors

The "IGFBP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGFBP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets